60 Degrees Pharmaceuticals Inc Dossier - Source-backed chat

60 Degrees Pharmaceuticals Inc

SXTPNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)2.02

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.33Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $4.7M

Enterprise Value $3.8M

Shares Outstanding 3.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

60 Degrees Pharmaceuticals (SXTP) is a high-risk, micro-cap specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases. While the company has successfully commercialized ARAKODA for malaria prevention and is showing promising clinical progress with Tafenoquine for babesiosis (including a 100% cure rate in expanded access trials), it faces severe financial constraints. The company reported a net loss of $7.37 million for FY2025 and $2.21 million for Q1 2026, with auditors raising substantial doubt about its ability to continue as a going concern. With cash reserves projected to last only through mid-September 2026, the company is highly dependent on dilutive equity financing (such as its ATM facility) or securing strategic partnerships. Consequently, a Hold rating is warranted until the company secures a longer cash runway or achieves major clinical/regulatory milestones.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.70

Mean target$3.70

High · most bullish analyst$3.70

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case is defined by a failure to secure additional funding before the cash runway expires in mid-September 2026, leading to severe operational disruption or insolvency. Alternatively, slow patient recruitment could delay clinical readouts, and continued downward pressure on the stock price could result in Nasdaq delisting despite previous reverse splits.

Base CaseCentral scenario

$1.6050%

In the base case, ARAKODA sales continue to grow modestly, but operating expenses and clinical trial costs keep the company in a net loss position. The company will likely execute further dilutive capital raises or utilize its authorized reverse stock split to maintain its Nasdaq listing. Clinical trials will progress slowly, with interim babesiosis data expected in late September 2026.

Bull CaseUpside scenario

$3.7030%

The bull case relies on the successful expansion of ARAKODA sales through new telehealth partnerships (such as Runway Health and GoodRx) and positive clinical readouts for Tafenoquine in treating hospitalized babesiosis patients. If the Phase 2 B-FREE study or the randomized hospital study yields strong efficacy data, it could pave the way for FDA Breakthrough Therapy Designation or a lucrative commercialization partnership, significantly reducing going concern risks and driving non-dilutive capital.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA-approved lead product (ARAKODA) already on the market for malaria prophylaxis, providing an established commercial foundation.
Strong clinical signal in babesiosis trials, including a 100% cure rate in its expanded access study with tafenoquine treatment.
Strategic commercial partnerships established with GoodRx and Runway Health to expand market reach and prescriber demand.

Key Investment Risks

Severe going concern risk with current cash reserves expected to fund operations only through mid-September 2026.
High risk of shareholder dilution due to frequent reliance on At-the-Market (ATM) offerings and public warrant issuances.
Nasdaq listing non-compliance risks, requiring a 1-for-4 reverse split in January 2026 and potential future splits to maintain the minimum bid price.

Thesis Invalidation Triggers

Inability to secure additional capital or strategic partnerships before mid-September 2026, leading to insolvency or restructuring.
Negative or inconclusive clinical data from the ongoing Phase 2 babesiosis trials.
Delisting from the Nasdaq Capital Market due to failure to maintain the minimum bid price.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.